J&J forecasts weak annual profit, misses revenue estimates
Reuters
Published Jan 22, 2020 08:19AM ET
(Reuters) - Johnson & Johnson (NYSE:JNJ) on Wednesday forecast full-year profit largely below expectations, after posting a rare miss on quarterly revenue as sales of some of its major drugs fell short of Wall Street expectations.
Shares of the healthcare giant, which were trading at a record high prior to the results, fell about 1.5% to $147 in premarket trading.
J&J's pharmaceuticals unit, which makes up half of the overall sales and produces blockbuster drugs such as Imbruvica and Stelara, has powered much of the company's recent growth even as it works to improve the performance of its medical device and consumer health units.
However, intense competition for some off-patent drugs such as prostate cancer drug Zytiga, coupled with pressure on prescription drug prices in the United States, has weighed on revenue at the top-earning unit.
Revenue at the pharma unit, which also makes antidepressant Spravato and plaque psoriasis drug Tremfya, rose 3.5% to $10.55 billion in the fourth quarter, but missed the average estimate of $10.63 billion, according to two analysts polled by Refinitiv.
Sales of psoriasis drug Stelara rose 17.7% to $1.70 billion, missing Credit Suisse's estimate of $1.79 billion. Cancer drug Imbruvica's sales rose 24.5% to $875 million, although they missed the brokerage's estimate of $907 million.
Medical device sales fell to $6.63 billion from $6.67 billion, also missing the average estimate of $6.69 billion according to Refinitiv data.
The company said it expects full-year 2020 adjusted earnings per share in the range $8.95 to $9.10, with the top end of the range meeting analysts' average estimate.
Litigation expenses fell to $264 million in the fourth quarter, from $1.29 billion a year ago.
J&J's net earnings rose to $4.01 billion, or $1.50 per share, in the quarter, from $3.04 billion, or $1.12 per share, a year earlier.
Excluding items, it earned $1.88 per share, beating the average analyst estimate by a cent, according to IBES data from Refinitiv.
Total sales rose 1.7% to $20.75 billion, below the average estimate of $20.80 billion. That was the company's first revenue miss in at least eight quarters.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.